Novel M. tuberculosis specific IL-2 ELISpot assay discriminates adult patients with active or latent tuberculosis by Alnwaisri H. et al.
PLoS ONE, 2018, vol.13, N6
Novel M. tuberculosis specific IL-2 ELISpot assay
discriminates adult patients with active or latent
tuberculosis
Alnwaisri H., Shuralev E., Singh M., Bartoloni A., D’Elios M.
Kazan Federal University, 420008, Kremlevskaya 18, Kazan, Russia
Abstract
© 2018 Della Bella et al. This is an open access article distributed under the terms of the
Creative  Commons  Attribution  License,  which  permits  unrestricted  use,  distribution,  and
reproduction in any medium, provided the original author and source are credited. Background
Tuberculosis (TB) still is a major worldwide health problem, with 10.4 million new cases in 2016.
Only 5–15% of people infected with M. tuberculosis develop TB disease while others remain
latently infected (LTBI) during their lifetime. Thus, the absence of tests able to distinguish
between latent infection and active tuberculosis is one of the major limits of currently available
diagnostic tools. Methods A total of 215 patients were included in the study as active TB cases
(n = 73), LTBI subjects (n = 88) and healthy persons (n = 54). Peripheral blood mononuclear
cells (PBMCs) were isolated from each patient and the LIOSpot® TB anti-human IL-2 ELISpot
assay was performed to test their proliferative response to M. tuberculosis antigens ESAT-6,
CFP-10  and  Ala-DH.  Statistical  analysis  was  performed  to  define  the  sensitivity  and  the
specificity of the LIOSpot® TB kit for each antigen used and to set the best cut off value that
enables  discrimination  between  subjects  with  active  TB  or  latent  TB  infection.  Results
Comparing the LIOSpot® TB results for each tested antigen between uninfected and infected
subjects and between people with latent infection and active TB disease, the differences were
significant for each antigen (p< 0.0001) but the ROC analysis demonstrated a high accuracy for
the Ala-DH test only, with a cut off value of 12.5 SFC per million PBMCs and the Ala-DH ROC
curve conferred a 96% sensitivity and 100% specificity to the test. For the ESAT-6 antigen, with
a best cut off value of 71.25 SFC per million PBMCs, a sensitivity of 86% and specificity of 36%
was obtained. Finally, the best cut off value for CFP-10 was 231.25 SFC per million PBMCs, with
a sensitivity of 80% and a specificity of 54%. Thus, as for IGRA assays such as Quantiferon and
T-Spot TB tests, ESAT-6 and CFP-10 are unable to distinguish LTBI from active TB when IL-2 is
measured. On the contrary, the IL-2 production induced by Ala-DH, measured by LIOSpot® TB
kit,  shows  high  sensitivity  and  specificity  for  active  TB  disease.  Conclusions  This  study
demonstrates that  the LIOSpot® TB test  is  a  highly  useful  diagnostic  tool  to  discriminate
between latent TB infection and active tuberculosis in adults patients.
http://dx.doi.org/10.1371/journal.pone.0197825
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